← Human Trials & Peer-Reviewed Studies
The effect of in vivo growth hormone treatment on blood gene expression in adults with growth hormone deficiency reveals potential biomarkers to monitor growth hormone therapy.
Plain-language guide to PMID 19849699 (2010): pilot clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 19849699
- Journal
- Clinical endocrinology
- Year
- 2010
- Study type
- Clinical Trial
- Authors
- Fernández-Pérez L et al. (9 authors)
- DOI
- 10.1111/j.1365-2265.2009.03732.x
What This Study Did, in Plain Language
What Was Tested
This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Growth hormone (GH) replacement therapy is presently utilized in the treatment of adult GH deficiency (AGHD).
Adult responses to GH treatment are highly variable and, apart from measurement of IGF-I, few tools are currently available for monitoring GH treatment progress.
As GH receptors are expressed in certain blood cell types, changes in gene expression in peripheral blood can reflect perturbations induced as a result of GH therapy.
Who Took Part
PubMed indexes the participants as young adults, adults and middle-aged adults, women only.
Blood was collected from ten women diagnosed with AGHD syndrome both before and 4 weeks after initiation of GH substitutive therapy.
How the Study Was Run
In design terms this was a pilot study.
It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.
The researchers have carried out a pilot study to identify GH-responsive genes in blood, and have assessed the utility of GH-responsive genes in monitoring GH therapy in AGHD.
RNA was extracted from peripheral blood mononuclear cells (PBMCs) and changes in response to GH were detected using microarray-based gene analysis.
What Was Measured
PubMed files the paper under topics including Blood Proteins, Diagnostic Techniques, Endocrine, Gene Expression, Gene Expression Profiling, Growth Disorders, Hormone Replacement Therapy and Human Growth Hormone.
What This Means in Plain Language
The paper is a pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2010 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.